Us Healthcare Stock With Potential

last updated on

Us Healthcare Stock With Potential

This Us Healthcare Stock Has Huge Potential

Eli Lilly (LLY) is a leading healthcare stock from the US market. They have a strong portfolio of drugs that are used in neuroscience, diabetes, and obesity.

Eli Lilly (LLY) has a strong position, and it was proved by their revenue, which jumped 38% y/y. In addition, the EPS of Eli Lilly also jumped by 51% during the same period.

Eli Lilly Revenue Will Be $60 Billion For Fy2025

According to the management, the revenue will be around $60-$62 billion for the fiscal year 2025. Now, that's a big number and shows the strength of Eli Lilly in the healthcare sector.

Incretin is a drug made by Eli Lilly for chronic weight management and diabetes. This drive has proved to be a major growth driver for the company's stocks.

In addition, Eli Lilly has also made a GLP-1 drug, which is also used for weight management and diabetes. In fact, the Mounjaro is one of the highest-selling drugs for type 2 diabetes in the US market.

Looking ahead, experts believe that Eli Lilly has the potential to capture an even bigger share of the GLP-1 drug market.

The next big thing for Eli Lilly is the GLP-1 therapy in oral form. This drug is called Orforglipron, and it has already shown strong results in the trials.

Once the company gets the regulatory approval for Orforglipron, we can expect a major upside in the Eli Lilly (LLY) shares. According to experts, Orogel will be more convenient for consumers and will also reduce the injection burden.

Last but not least, Eli Lilly is also actively involved in making medicines for other areas such as cardiometabolic health, Alzheimer's, and so on.

Overall, Eli Lilly has huge potential, and that's why it trades at a 31.2x of its forward earnings. But, this valuation of Eli Lilly is totally right as they have a strong portfolio of drugs and have many more in the pipeline.

Trending Stories